Evogene Ltd. (EVGN): VRIO Analysis [Mar-2026 Updated]

Unlock the strategic DNA of Evogene Ltd. (EVGN) as we dissect its core competencies through the rigorous VRIO framework, testing its resources for true Value, Rarity, Inimitability, and Organization. This distilled summary cuts straight to the heart of its competitive standing, revealing precisely where its sustainable advantages lie - or where critical gaps threaten its market leadership. Engage with the analysis below to grasp the immediate implications of these findings.

Evogene Ltd. (EVGN) - VRIO Analysis: 1. ChemPass AI Generative Engine

You’re in the process of evaluating Evogene Ltd. (EVGN) after their major strategic pivot, and the core of that new direction is clearly the ChemPass AI engine. Honestly, this isn't just another piece of software; it’s the central asset they are betting the company on, especially after realizing about $18.71 million from the ICL transaction involving other tech earlier in 2025. This engine, which powers their small molecule discovery for pharma and ag-chem, needs a hard look through the VRIO lens to see if it truly offers a lasting edge.

Here’s the quick math on what this engine means for their competitive standing, based on their Q3 2025 position where they held $16.0 million in cash. The entire company is now streamlined around this technology, which is a big organizational shift following cost reductions and divestitures earlier in the year.

ChemPass AI Generative Engine - VRIO Assessment

The technology itself is clearly valuable and rare, especially with the recent completion of its generative AI foundation model, version 1.0, in June 2025. What this estimate hides, though, is the actual time-to-market advantage it delivers versus competitors who might be using off-the-shelf AI tools. Still, the organizational commitment is defintely there; they sold off other assets to fund this focus.

Here is a breakdown of the strategic implications:

• Value Driver: Focus on Pharma R&D, a higher-margin opportunity.
• Risk Mitigation: Reduces reliance on slower, traditional discovery methods.
• IP Potential: Facilitates development of strong, defensible IP portfolios.
• Operational Alignment: Reduced operating expenses to $7.7 million (nine months 2025) show cost discipline supporting the core tech.

Finance: draft 13-week cash view by Friday.

Evogene Ltd. (EVGN) - VRIO Analysis: 2. Computational Predictive Biology (CPB) Platform

Value

The overarching system combines deep science with big data and AI to optimize product development across all their tech-engines. This platform is the result of over a decade long multidisciplinary effort, at an investment of tens of millions of dollars.

Rarity

While AI platforms exist, Evogene's specific architecture integrating microbes, small molecules, and genetics is specialized. The CPB platform's core components for product development include:

• Microbes
• Small molecules
• Genetic elements

Imitability

Competitors can build AI, but replicating the specific scientific knowledge embedded in the CPB platform takes time. The platform's application spans multiple life-science segments, demonstrating breadth:

Organization

The recent divestitures suggest a clearer focus on exploiting this platform's core strengths moving forward. As of September 30, 2025, Evogene held consolidated cash of $16.0 million. Research and development expenses, net of non-refundable grants, for the first half of 2025 were approximately $4.8 million, a decrease compared to $6.5 million in the first half of 2024.

Competitive Advantage

Temporary. It's strong now, but the pace of AI development means others could catch up if Evogene doesn't keep innovating the platform itself. Total R&D expenses for the 12 months of 2024 were approximately $16.6 million, a decrease from approximately $20.8 million in the 12 months of 2023.

Evogene Ltd. (EVGN) - VRIO Analysis: 3. AgPlenus Integration and Ag-Chemical Focus

Value: Provides an established, revenue-generating channel (AgPlenus) to immediately apply ChemPass AI for next-generation crop protection products. Revenues for the 12 months of 2024 reached approximately $8.5 million, an increase from approximately $5.6 million in the year 2023, driven partly by AgPlenus\'s collaboration with Bayer. AgPlenus utilizes Evogene\'s ChemPass AI tech-engine for developing novel crop protection products.

Rarity: Moderate. Having an operating ag-chemical subsidiary with existing development activity is rarer than just having the AI. AgPlenus had APH1, a broad weed-control spectrum herbicide candidate, as its most advanced product candidate in its pipeline as of the first quarter of 2023.

Imitability: Moderate. Competitors can acquire or build ag-chem pipelines, but integrating it with Evogene's specific AI is the key barrier. The integration involves leveraging the ChemPass AI, which was enhanced by a generative AI foundation model trained on a proprietary dataset of approximately 38 billion molecular structures.

Organization: High. Management specifically integrated AgPlenus deeper into core operations to maximize this synergy, including a 40% workforce reduction at AgPlenus in July 2025 as part of the optimization.

Competitive Advantage: Sustained. The combination of a focused AI engine and an existing, relevant commercial arm creates a powerful, integrated offering.

Key operational and financial data points related to the AgPlenus integration:

The integration aims to unlock deeper synergies and operational efficiency by applying ChemPass AI to AgPlenus's development pipeline.

• AgPlenus had a collaboration agreement with Corteva initiated in 2020.
• Revenues for the nine months ending September 30, 2025, were lower than the prior year, partially due to the absence of a one-time payment from Bayer recognized in the first quarter of 2024.

Evogene Ltd. (EVGN) - VRIO Analysis: 4. GeneRator AI Tech-Engine

GeneRator AI is one of Evogene's three core technology engines, specifically focused on the discovery and development of products based on genetic elements. This represents a distinct innovation pathway separate from the small molecule focus of ChemPass AI.

The engine's value is demonstrated through its application in Casterra Ag, which develops high-yield castor seed varieties for biofuel and other industries. Casterra delivered 250 tons of castor seeds to an African partner in Q1 2025, surpassing the 215 tons delivered in all of 2024.

Having a dedicated, developed engine for genetic elements is considered moderately rare compared to the more common general drug discovery AI platforms. Evogene maintains three unique tech-engines: MicroBoost AI, ChemPass AI, and GeneRator AI.

The technology represents a distinct, developed technological track requiring specific data sets and model training, suggesting a high degree of imitability difficulty.

The organizational commitment is currently moderate, as the company has strategically prioritized the ChemPass AI engine. This is evidenced by the recent sale of the MicroBoost AI for Ag engine to ICL for approximately $3.5 million.

The competitive impact is currently secondary to the ChemPass AI focus, positioning the advantage as temporary, despite the engine being a valuable resource.

The strategic realignment is reflected in the following financial figures:

• R&D Expenses for Q1 2025 were approximately $3.2 million, a decrease from approximately $4.8 million in Q1 2024.
• Total operating expenses for Q3 2025 were reduced to approximately $2.9 million, down from $6.6 million in Q3 2024.
• The agreement to sell most of Lavie Bio and the MicroBoost AI for Ag platform is expected to inject approximately $18.75 million into Evogene's cash position.
• Casterra's seed sales in Q1 2025 surpassed the total delivered in 2024 by 15 tons (250 tons vs. 215 tons).

Evogene Ltd. (EVGN) - VRIO Analysis: 5. Casterra Subsidiary and Castor Seed Assets

Casterra Ag Ltd. operates as the industrial applications segment for Evogene, focusing on developing improved castor bean seeds for industrial uses, including feedstock for biofuels.

Value: Generates direct revenue from seed sales and offers a unique, non-AI-core business line that provides diversification and potential value realization. Casterra's revenue contribution is evident in the consolidated figures, with total revenues for the year 2024 reaching approximately $8.5 million, an increase from approximately $5.6 million in 2023, an increase partly attributed to Casterra's seed sales. In the first half of 2025, total revenues amounted to approximately $3.2 million, compared to $2.3 million in the first half of 2024, primarily driven by higher seed sales generated by Casterra. Sales and Marketing expenses for the first half of 2024 were approximately $1.9 million, showing an increase attributable to increased sales and marketing activities in Casterra.

Rarity: Moderate. Owning industrial-scale castor seed IP and sales channels is a tangible, non-computational asset. Casterra secured initial purchase orders in 2023 totaling $11.3 million for its proprietary castor plant seeds. An additional purchase order valued at approximately $440K was announced on June 25, 2024. As of June 25, 2024, the remaining revenue from unsupplied orders was approximately $8.4 million.

Imitability: Moderate. Replicating superior castor seed varieties and the associated commercialization know-how is a biological/agricultural challenge. Casterra's seeds are developed utilizing Evogene's GeneRator AI tech-engine. In Q4 2024, Casterra delivered approximately 76 tons of castor seeds, while in February 2025 alone, the company delivered approximately 250 tons of castor seeds.

Organization: Moderate. Management intends to focus on generating value through its holdings here, signaling active management, not abandonment. As of June 30, 2024, Evogene's consolidated cash of approximately $20.9 million did not include $8.4 million of expected payments for Casterra's open purchase orders. Sales and Marketing expenses for the first half of 2024 were approximately $1.9 million, a slight increase from approximately $1.7 million in the same period in the previous year, with the increase mainly attributable to increased sales and marketing activities in Casterra.

Competitive Advantage: Temporary. It’s a good asset, but it doesn't directly benefit from the company's primary AI strategy. The global biodiesel market size was estimated at $36.48 billion in 2022 and is expected to reach around $79.12 billion by 2032. The global Castor Oil Market reached US$ 1.23 billion in 2022 and is expected to reach US$ 1.98 billion by 2030.

Financial Performance Metrics Related to Casterra:

Casterra's operational and commercial milestones:

• Casterra announced receiving a $440K purchase order on June 25, 2024, to supply castor seeds to a new African country in 2024.
• The company's initial 2023 purchase orders totaled $11.3 million for supply during 2023 for biofuel production in Africa.
• Casterra operates an R&D center in Israel and a local production site in Brazil, with another site in Zambia.

Evogene Ltd. (EVGN) - VRIO Analysis: 6. Post-Realignment Cost Structure

Value: Significantly reduced operating expenses, with Q3 2025 operating expenses at approximately $2.9 million compared to approximately $6.6 million in Q3 2024, extending runway. As of the end of the third quarter of 2025, the company's cash and short-term bank deposits balance was approximately $16.0 million.

The new expense level of approximately $2.9 million for Q3 2025 is expected to be maintained going forward.

Rarity: Low. Cost-cutting is common, but the completion of a major plan is a specific, timely achievement. The organizational change and cost reduction initiative was executed as part of the strategic transition.

Imitability: Low. Competitors can cut costs, but this is a result of Evogene's specific past restructuring decisions. The organizational realignment and cost-reduction plan was most of which was completed by the end of the second quarter of 2025.

Organization: High. The organizational realignment was decisive and completed by Q2 2025, showing management's ability to execute tough changes. This is further evidenced by the reduction in operating loss for the nine months of 2025 to approximately $8.8 million compared to approximately $15.3 million in the same period of 2024.

Detailed expense components contributing to the cost structure change include:

• General and administrative expenses for Q3 2025 decreased to approximately $1.1 million compared to approximately $2.8 million in Q3 2024.
• Research and development expenses, net of non-refundable grants, for the nine months of 2025 were approximately $6.2 million, a decrease of approximately $3.6 million compared to $9.8 million in the nine months of 2024.
• R&D expenses in Q3 2025 were approximately $1.4 million, down from approximately $3.3 million in Q3 2024.
• Sales and marketing expenses for the nine months of 2025 totaled approximately $1.1 million, compared to approximately $1.6 million in the same period of 2024.
• Sales and marketing expenses for Q3 2025 were approximately $0.4 million, reflecting a slight decrease of approximately $0.1 million compared to approximately $0.5 million in Q3 2024.

Competitive Advantage: Temporary. This efficiency improves the current financial picture but is not a source of long-term revenue or IP advantage. The operating loss for Q3 2025 was approximately $2.7 million, a decrease from approximately $5.9 million in Q3 2024, primarily due to decreased operating expenses.

Evogene Ltd. (EVGN) - VRIO Analysis: 7. Financial Liquidity Post-Divestiture

Value: A cash balance of approximately $16.0 million as of September 30, 2025, provides a solid buffer following the sale of Lavie Bio and MicroBoost AI for Ag assets.

Rarity: Moderate. The cash position is bolstered by specific, non-recurring asset sales, making the current level unique to this point in time. The transaction involved the sale of the majority of Lavie Bio's activity for an aggregate consideration of US$15.25 million and the MicroBoost AI tech-engine for approximately $3.5 million.

Imitability: Low. Competitors can raise capital, but this specific cash pile is a direct result of Evogene's recent transactions. The sale generated income, net, of approximately $7.9 million in the third quarter of 2025 alone.

Organization: High. The company successfully monetized non-core assets to fund its focused strategy. The cash balance as of September 30, 2025, reflects the proceeds from this sale.

Competitive Advantage: Temporary. Cash is fungible; the advantage lies in how they deploy it to advance ChemPass AI. The company's operational cash usage provides context for this liquidity:

• Consolidated cash usage during the third quarter of 2025, excluding the cash generated from the sale, was approximately $3.5 million.
• Cash usage excluding Lavie Bio and Biomica for Q3 2025 was approximately $2.3 million.

The financial position as of September 30, 2025, compared to prior periods highlights the impact of the divestiture:

Evogene Ltd. (EVGN) - VRIO Analysis: 8. Expertise in Microbiome Therapeutics (Biomica)

Value: Retained scientific knowledge and development capability in microbiome-based therapeutics, powered by the MicroBoost AI engine, despite scaling down operations. Evidence includes the BMC128 Phase I study showing early signs of immune activation within 14 days of monotherapy. The underlying computational platform, PRISM, is powered by Evogene's MicroBoost AI tech-engine.

Rarity: Moderate. Deep expertise in microbiome R&D, even if streamlined, is a specialized asset in the life sciences. Biomica is a clinical-stage company focused on this area.

Imitability: High. Building a team with this specific therapeutic focus and underlying AI knowledge, such as the PRISM platform, is a multi-year effort.

Organization: Moderate. While operations were scaled down, the underlying IP and scientific team structure likely remain a resource. The subsidiary previously secured a financing round of $20 million.

Competitive Advantage: Temporary. Its competitive impact is muted until Biomica's activities are re-prioritized or monetized, reflected in reduced R&D expenses for the nine months of 2025 being approximately $6.2 million, down from $9.8 million in the same period of 2024, largely due to reduced Biomica R&D activity.

Key Operational and Financial Data Points:

Underlying Technological Assets:

• Microbiome-based therapeutics development utilizing Evogene's MicroBoost AI tech-engine.
• Drug candidates identified and designed using the PRISM proprietary computational platform.
• Pipeline includes BMC128 (Immuno-oncology) and BMC333 (Inflammatory Bowel Disease - IBD).

Evogene Ltd. (EVGN) - VRIO Analysis: 9. Exclusive Licensing and Collaboration Framework

Finance: Q4 2025 Cash Burn Projection (Based on Q3 Operating Expenses)

The consolidated cash usage for Evogene and its other subsidiaries, excluding Lavie Bio and Biomica, during the third quarter of 2025 was approximately $2.3 million. Based on this core operational cash usage rate, the projected Q4 2025 cash burn is $2.3 million, assuming a maintained expense level going forward.

Value: The established model of using tech-engines to develop products via exclusive licenses and strategic partnerships allows for non-dilutive value capture.

The framework captures value through licensing Evogene's AI Tech-Engines to third parties, including its subsidiaries, for product development. The company utilizes three unique tech-engines: MicroBoost AI (microbes), ChemPass AI (small molecules), and GeneRator AI (genetic elements).

Rarity: Moderate. Many firms do this, but Evogene's framework is tailored to their specific AI output (molecules, microbes, genes).

The framework is tailored to commercialize outputs from distinct, proprietary AI platforms focused on specific biological components. The company has established collaborations with leading life-science companies. The sale of the MicroBoost AI for Ag tech-engine to ICL for a total of $18.71 million in July 2025 demonstrates a realized value event for one of these specific outputs.

Imitability: Moderate. The legal and operational framework for these deals is established, reducing friction for new partners.

The established structure for value capture includes defined revenue streams from collaborations and licensing. The legal and operational framework is designed to reduce friction for new partners. The company recorded a gain on sale of approximately $6.4 million in Q3 2025 related to the sale of Lavie Bio's assets and MicroBoost AI for Ag.

• License fees & R&D reimbursement.
• Dividends to Evogene as a shareholder.
• Significant one-time-payment upon an exit event.
• Upfront payments, R&D fees, Milestone payments, Royalties from sale of end-products.

Organization: High. This framework is how they translate their R&D into realized income, as seen with past deals.

The framework is the mechanism for translating R&D from the ChemPass AI tech engine and others into realized income. As of September 30, 2025, Evogene held consolidated cash, cash equivalents, and short-term bank deposits of approximately $16.0 million. The operating loss for the third quarter of 2025 was approximately $2.7 million, a decrease from approximately $5.9 million in Q3 2024, reflecting streamlined operations.

Competitive Advantage: Sustained. A proven, repeatable mechanism for external value extraction is a key operational strength.

The repeatable mechanism for external value extraction, involving both subsidiaries and external partners like Bayer and Corteva (historical validation), provides a sustained operational strength. The company's total operating expenses, net, for Q3 2025 were approximately $2.9 million, down from approximately $6.6 million in Q3 2024, showing cost discipline supporting the framework's efficiency.